Zobrazeno 1 - 10
of 40
pro vyhledávání: ''
Publikováno v:
European Neurology. 80:163-170
Background: To assess whether intensive statin therapy reduces the occurrence of microemboli in patients with acute ischemic stroke. Methods: Patients with acute ischemic stroke within 72 h of onset were randomized to the intensive statin (atorvastat
Publikováno v:
Cerebrovascular Diseases. 34:229-239
Background: Clopidogrel 75 mg once daily is licensed in Japan for the prevention of recurrent ischemic cerebrovascular events in adults as the usual dosage. However, a lower dose (50 mg) is an option in patients at an increased risk of bleeding depen
Publikováno v:
European Neurology. 65:317-322
Aims: This study evaluates the efficacy and tolerability of long-term controlled-release (CR) oxycodone + pregabalin in patients with non-cancer pain, in a real-life setting. Methods: Patients (n = 1,051) with chronic uncontrolled non-cancer pain rec
Autor:
V. Di Piero, Edoardo Vicenzini, Gian Luigi Lenzi, Maria Chiara Ricciardi, Gaia Sirimarco, Carmela Zuco
Publikováno v:
Cerebrovascular Diseases. 32:447-453
Background: Mannitol infusion is widely used in clinical practice to reduce perilesional edema in intracerebral hemorrhage (ICH), though no controlled studies have yet provided evidence of its effects on clinical outcome or on cerebral blood flow imp
Autor:
Hideaki Nakagaki, Fumio Miyashita, Masahiro Yasaka, Ryo Itabashi, Takahiro Kuwashiro, Kazuo Minematsu, Hiroaki Naritomi
Publikováno v:
Cerebrovascular Diseases. 29:446-453
Background: The relationship between warfarin administration and the frequent development of enlarged hematomas in patients with acute intracerebral hemorrhage (ICH) is controversial. The present study was carried out to examine this issue. Methods:
Publikováno v:
Neurodegenerative Diseases. 7:219-231
Background: The anti-Parkinson monoamine oxidase B inhibitor rasagiline appears to be the first neuroprotective disease-modifying therapy in early-stage Parkinson’s disease (PD). Objective: Using a polypharmacy paradigm, we tested whether the disti
Autor:
Dana Leifer, Greg Neils, Tania Corporan, Ken Cheung, Rui Liu, Ralph L. Sacco, Mitchell S.V. Elkind, Joshua Stillman, Robert B. MacArthur, Ellinor I.B. Peerschke, Howard Andrews
Publikováno v:
Cerebrovascular Diseases. 28:266-275
Background: Hydroxymethylglutaryl coenzyme A reductase inhibitors (‘statins’) reduce the neuronal injury in dose-dependent fashion in rodent stroke models. We sought to determine whether lovastatin at doses above those currently approved can be a
Autor:
Andrew D Barreto, Sheryl Martin-Schild, Hashem Shaltoni, Hen Hallevi, Sean I Savitz, Anitha T. Abraham, James C. Grotta, Nicole R. Gonzales
Publikováno v:
Cerebrovascular Diseases. 28:595-600
Background: There is no proven treatment for stroke progression in patients with subcortical infarcts. Eptifibatide, a glycoprotein IIb/IIIa inhibitor, might halt stroke progression by improving flow in the microcirculation. Methods: We conducted a r
Autor:
Bernd Jilma, Dan Atar, Alex N. Pokov, Victor L. Serebruany, Alex I. Malinin, D. F. Hanley, Wendy C. Ziai
Publikováno v:
Cerebrovascular Diseases. 21:98-105
Background: Although controversial, the phenomenon of aspirin resistance (AR) has been correlated in some small studies with poor clinical outcomes in patients with coronary artery disease. Even less is known regarding the role of AR in the poststrok
Autor:
Niaz Ahmed, Nils Wahlgren
Publikováno v:
Cerebrovascular Diseases. 15:235-243
Background: Lowering of blood pressure (BP) in the acute phase of stroke is reported both to worsen and to improve the outcome. To investigate whether heterogeneity exists between stroke subtypes in the response to BP lowering, we analysed data from